D-0878-2023 Class II Terminated

Recalled by The Harvard Drug Group — La Vergne, TN

FDA drug recall D-0878-2023 was initiated by The Harvard Drug Group on Jun 16, 2023 and is designated Class II. Reason for recall: Packaging defect: blister packaging inadequately sealed. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 3876 cartons.

Recall details

Product Type
Drugs
Report Date
Jul 5, 2023
Initiation Date
Jun 16, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3876 cartons

Product description

Tramadol Hydrochloride Tablets, USP 50 mg, Unit Dose 100-Count Tablets Rx only, Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-7179-61

Reason for recall

Packaging defect: blister packaging inadequately sealed.

Distribution pattern

Nationwide in the U.S.

Code information

Lot #: M04343, Exp. 04/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0878-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0878-2023. Report a data issue: hello@regdatalab.com.